Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGARO UC 301 ontamalimab induction study in moderate to severe ulcerative colitis
NL-OMON50514Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ontamalimab in autoimmune colitis (3 arms), sponsored by Takeda. Primary endpoint: Induction of remission. Started Sep 2018; status: completed.
02
Drugs
ontamalimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON50514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50514.